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Abstract
Background—This study examines whether adding nicotine replacement therapy (NRT) to
cognitive behavioral therapy (CBT) for pregnant smokers increases rates of smoking cessation.
Methods—An open-label randomized trial (Baby Steps, n = 181) of CBT-only versus CBT+NRT
(choice of patch, gum, or lozenge; 1:2 randomization) was used. Data were collected from 2003
through 2005; analyses were conducted in 2006 and 2007. Outcomes were biochemically
validated self-reported smoking status at 7-weeks post-randomization, 38-weeks gestation, and 3-
months postpartum.
Results—Women in the CBT+NRT arm were almost three times more likely than women in the
CBT-only arm to have biochemically validated cessation at both pregnancy timepoints (after 7
weeks: 24% vs 8%, p = 0.02; at 38-weeks gestation: 18% vs 7%, p =0.04), but not at 3-months
postpartum (20% vs 14%, p=0.55). Recruitment was suspended early by an independent Data and
Safety Monitoring Board when an interim analysis found a greater rate of negative birth outcomes
in the CBT+NRT arm than in the CBT arm. At the final analysis the difference between the arms
in rate of negative birth outcomes was 0.09 (p=0.26), adjusted for prior history of preterm birth.
Conclusions—The addition of NRT to CBT promoted smoking cessation in pregnant women.
This effect did not persist postpartum. More data are needed to determine the safety and to
confirm the efficacy of NRT use during pregnancy.
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INTRODUCTION
Smoking during pregnancy is associated with numerous adverse pregnancy outcomes,
including low birthweight, miscarriage, stillbirth, placenta previa, placental abruption, and
cognitive impairments.1–4 Despite awareness of the health consequences of smoking during
pregnancy, at least half of women who smoke will continue to smoke throughout pregnancy.
5
Cognitive behavioral therapy (CBT) interventions are effective during pregnancy6–24;
pooled efficacy in one meta-analysis was 0.95 (95% confidence interval [CI]=0.92–0.97).25
Effectiveness is reduced among women who have a partner who smokes, are less educated,
and are heavy smokers (smoke >10 cigarettes per day).11, 12, 26–29 Given the considerable
risk of pregnancy complications related to smoking, more effective interventions are needed.
Nicotine replacement therapy (NRT) is highly effective in nonpregnant smokers30 and is
widely available over the counter. Because evidence suggests that NRT use during
pregnancy is not more harmful to the fetus than ad libitum smoking (in terms of maternal
and fetal hemodynamics and nicotine exposure),31–33 there has been considerable interest
in the use of NRT to improve cessation rates in pregnant smokers.34, 35
Previous randomized trials of NRT in pregnancy have shown reductions in smoking rates
(5% absolute reduction) similar to other interventions.25, 36–38 In one trial,37 NRT was
used as part of a multimodal intervention along with CBT, so direct estimation of the effect
of NRT alone was not possible. In two other trials,36, 38 adherence to the use of nicotine
patches was low.
To assess whether the addition of NRT to CBT resulted in improved smoking cessation
rates, a randomized, open-label trial comparing CBT-only to CBT+NRT (choice of gum,
lozenge, or patch) in pregnant smokers was conducted.
METHODS
Eligibility and Recruitment
The protocol was approved and monitored by the Institutional Review Boards of all
participating institutions. Women were eligible if they were between 13- and 25-weeks
pregnant, had smoked at least 100 cigarettes in their lifetime, currently smoked five or more
cigarettes per day, were planning to continue prenatal care in one of the participating clinics,
were aged at least 18 years, and spoke English. Recruitment occurred from May 2003
through August 2005. Analysis of data occurred in 2006 and 2007.
Participant eligibility was confirmed by an obstetrician reviewer. Women were excluded
from the trial if they had: (1) evidence of cognitive or mental health problems (e.g.,
diagnosis of mental disorder in chart or interviewer or support specialist suspected
problems); (2) evidence of possible drug or alcohol addiction; or (3) documented history of
placental abruption, poorly controlled hypertension, cardiac arrhythmia, myocardial
infarction within the past 6 months, previous pregnancy with congenital anomaly, or family
history of congenital anomalies.
Procedure
Recruitment is reported in detail elsewhere.39 There were three phases of recruitment: (1)
chart audit, (2) baseline survey, and (3) the first intervention session. Women were recruited
from 14 clinical sites in Durham, Raleigh, and Fayetteville, North Carolina, including sites
that provide prenatal care to active-duty soldiers and their dependents (Womack Army
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Medical Center at Fort Bragg). Obstetric nurses assessed smoking status for all new patients.
Introductory letters and brochures describing the study were sent via United States Postal
Service (USPS) 2-Day Priority Mail to these self-identified smokers. Women were
instructed to call project staff using a toll-free number within 1 week if they did not want to
be contacted.
Study staff performed a chart audit to determine a woman’s medical eligibility. A survey
company contacted all medically eligible women to reassess smoking status and gestational
age; surveyors obtained verbal consent and conducted the baseline survey. At the end of the
survey, the women were asked their willingness to meet with a “support specialist” at their
next prenatal appointment to discuss their smoking. If they agreed to set a quit date in the
next 2–3 weeks and consider using NRT, support specialists randomized the women to the
trial during the first intervention session.
Study Design and Intervention
A computerized random number generator was used to derive a list for randomization. Each
support specialist had a handheld device that contained a randomization list. The
randomization list was stratified by support specialist and gestational age (≤ 16 weeks versus
>16 weeks). Women were randomized using a 1:2 allocation to CBT-only or CBT+NRT to
allow comparisons between women who chose intermittent therapies (gum and lozenge)
versus continuous therapy (patch).
The trial did not include a placebo NRT because the efficacy of NRT has been shown
consistently among nonpregnant populations. Also, placebos for all of the forms of NRT
were not available at the time of study initiation.
All women received six one-on-one counseling sessions (five face-to-face at prenatal visits
and one via telephone) designed to enhance motivation and develop skills needed to quit
smoking. The timing of the intervention contacts was designed to be relapse-sensitive (close
in time to the woman’s quit date) and to coincide with prenatal visits.40,41 The first
counseling session involved support specialists consenting, randomizing, and giving women
a “quit kit”: a smoking cessation booklet designed for pregnant smokers (Make Yours a
Fresh Start Family), water bottle, straws, hard candy, an exercise band, and a stress
management tape. Support specialists helped the women devise an action plan. For women
in the CBT+NRT arm, support specialists presented the advantages and disadvantages of the
three types of NRT (patch, gum, and lozenge) and helped the women make an informed
choice. Women received their first dose of NRT at the session (see below for dosing details).
This session lasted a mean of 64.7 minutes (SD=15.8): CBT: M=61.7, SD=16.7; CBT
+NRT: M=66.1, SD=15.7. After the first session, each woman was mailed a card detailing
her action plan.
The second counseling session occurred over the phone about 48 hours after the quit date.
The purpose of the call was to discuss alternatives if the quit attempt was not successful. The
third session typically occurred 1 to 2 weeks after the phone session at the woman’s next
prenatal visit. The fourth, fifth, and sixth sessions occurred between 2 and 4 weeks apart,
depending on the timing of the prenatal appointments. In all sessions, support specialists
attempted to increase the women’s motivation, self-efficacy, and skills. In addition to the
smoking-specific content, support specialists covered a relevant content area (stress,
rewards, social support, and relapse prevention). This gave support specialists topics to
discuss when a woman was still smoking. Sessions 2–6 lasted a mean of 25.7 minutes
(SD=14.1): CBT: M=23.6, SD=10.7; CBT+NRT: M=27.0, SD=13.9.
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The counseling protocol was based on Motivational Interviewing,42 the Transtheoretical
Model of Behavior Change,43 and Social Cognitive Theory.44 All support specialists
attended 40 hours of training. Throughout the trial, they received supervision of their cases
to assure adherence to Motivational Interviewing principles and the study protocol.
Dosing and Dispensing of NRT
Women in the CBT+NRT arm were allowed to choose the nicotine patch, gum, lozenge, or
no NRT at all; they could also switch delivery modalities. Each woman’s NRT dose was
based on current smoking level. For those who chose the patch, they were instructed to wear
it for waking hours only (16 hours) as is recommended during pregnancy.34 The doses for
the patch were: fewer than 10 cigarettes/day = 7 mg /day; 10–14 cigarettes/day = 14 mg /
day; 15 or more cigarettes/day =21 mg /day. For those who chose the gum or lozenge, they
were instructed to use one 2-mg piece for every cigarette they smoked per day. The women
were given enough NRT to last until the next scheduled face-to-face session. Overall, they
were encouraged to use NRT for 6 weeks to minimize nicotine exposure in the third
trimester. However, if a woman felt that she would return to smoking, she was instructed to
use NRT longer. Before the women left with their NRT, each was required to sign a contract
promising not to smoke while using NRT.
Assessments
Telephone surveys were conducted with the women three times during pregnancy (at
baseline, 7-weeks post-randomization, 38-weeks gestation) and once at 3-months
postpartum. The primary outcome was self-reported 7-day point prevalence abstinence at the
two pregnancy follow-up timepoints. Saliva samples for cotinine validation were collected
at the intervention session that coincided with each telephone survey from all women
regardless of smoking status. At the 3-month postpartum follow-up, saliva samples were
collected via mail only from self-reported nonsmokers. Participants were paid $10 each time
they provided a saliva sample and $10 in advance for each telephone survey ($70 total).
Safety Monitoring
To monitor safety, study staff conducted monthly chart audits to assess maternal blood
pressure; urine dipstick (protein, blood, glucose, leukocyte esterase); maternal weight;
fundal height as a measure of fetal growth; and examination for the presence of edema,
threatened miscarriage, congenital anomalies, pelvic or abdominal surgical procedures, deep
venous thrombosis, and malignancy. Study obstetricians reviewed these audits to determine
whether a woman should be removed from NRT. Also, at any time, a woman’s personal
obstetrician could request removal from NRT. In addition, if a woman reported wanting
more NRT, her saliva was tested using a rapid assay assessment (NicAlert™, Craig Medical
Distribution, Inc., Vista, CA) to ensure that her cotinine level did not exceed her baseline
value, taken when she was smoking. Each woman also provided a breath sample to test for
carbon monoxide (CO). Any woman with an exhaled CO >10 ppm and with a NicAlert
greater than her baseline value was instructed to stop using the NRT. Finally, study staff
audited the women’s delivery and neonatal records to assess pregnancy outcomes and
maternal medical history.
Study staff identified potential serious adverse events (SAEs) that could be attributed to
smoking or nicotine (preterm birth<37 weeks, low birthweight<2500 grams, pre-eclampsia,
placental abruption, placental previa, neonatal ICU admission, fetal demise, and infant
death). An independent Data and Safety Monitoring Board (DSMB) reviewed all SAE
reports. Prior to the trial beginning, the DSMB decided that a statistically significant twofold
increase in adverse birth outcomes would result in suspension of study enrollment. At a
scheduled interim analysis with approximately half of participants enrolled, the DSMB
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found a twofold difference in SAEs between arms. Because of an a priori stopping rule, they
recommended stopping enrollment. The DSMB did state, however, that they did not believe
the SAEs were related to NRT use.
Analysis
The study was initially designed to enroll 300 women to have 91% power (two-sided
α=0.025) to detect an arm difference in 7-week post-randomization quit rates of 0.20 versus
0.40. Three hundred patients also gave 80% power (two-sided α=0.025) to detect an arm
difference in 38-week gestation quit rates of 0.13 versus 0.28.
For analyses of smoking cessation, an intent-to-treat analysis was used in which all women
lost to follow-up were considered smokers. Smoking cessation at 7-weeks post-
randomization and at 38-weeks gestation were the primary endpoints, and smoking cessation
at 3-months postpartum was a secondary endpoint. Arm differences in cessation (yes/no),
adverse events (yes/no), and other dichotomous endpoints were tested with the chi-square
test and described with the risk difference (RD) and its 95% CI. Arm differences in
birthweight, gestational age, and number of cigarettes smoked per day were tested with the
Wilcoxon two-sample test and described with means ± standard deviation. The logistic
regression model was used to test for arm differences in cessation rates controlling for
number of completed sessions. The logistic regression model was also used to test for arm
differences in adverse event rates, controlling for history of preterm birth. Because the study
had two primary endpoints, a two-sided α of 0.025 was used to test for arm differences,
while all other statistical tests used a two-sided α of 0.05. SAS version 9.1 was used to
conduct all analyses.
RESULTS
Recruitment and Enrollment
Figure 1 illustrates recruitment, enrollment, and retention. The CBT-only and CBT+NRT
arms did not differ statistically in their follow-up rates at 7-weeks post-randomization, 38-
weeks gestation, or 3-months postpartum: 63% vs 76% (p=0.08), 49% vs 60% (p=0.20), and
66% vs 62% (p=0.74), respectively. Compared to women who completed the trial, women
lost to follow-up had a greater probability of having had a previous pregnancy loss (64% vs
42%, p=0.01) and having made a 24-hour quit attempt during a prior pregnancy (66% vs
44%, p=0.007). They also smoked more cigarettes per day (means of 14 (±7) vs 10 (±5),
p<0.001).
Participant Characteristics
Table 1 describes participant characteristics. By chance alone, an imbalance between the
arms was observed in the proportion of women with a prior preterm birth (12% in CBT-only
vs 32% in CBT+NRT).
Intervention Outcomes
Biochemical confirmation of self-reported abstinence—The proportion who
returned saliva samples differed significantly between the CBT+NRT and CBT-only arms
with more women in the CBT+NRT arm providing samples at the 7-week post-
randomization (65% vs 47%, respectively, p=0.03), but not at the 38-week gestation follow-
up (47% vs 39%, p= 0.33) or 3-month follow-up (42% vs 25%, p=0.68). The nondisclosure
rate was 14% in the CBT arm and 15% in the CBT+NRT arm.
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Adherence to NRT—Of the 122 women in the CBT+NRT arm, 72 selected the patch, 32
selected the gum, 12 selected the lozenge, and six opted to use no NRT. Study staff
dispensed a mean of 40 patches to the women (this would last 5.7 weeks); however, women
reported using a mean of only 23.4 patches (lasting 3.3 weeks). Study staff dispensed
enough gum to last the women 18 days; they reported using gum for 8 days. Staff dispensed
lozenges to last 19 days; the women reported using lozenges for a mean of 4 days. Overall,
76% of the women in the CBT+NRT arm reported using some form of NRT. Nineteen
percent of those who were unable to quit with one formulation chose another. Only four
women in the CBT arm reported NRT. Twelve women of 112 who completed the 3-month
survey reported using NRT; two were in the CBT arm. Only one woman had a CO reading
greater than 10 ppm, indicating that she was smoking. Five women had NicAlert readings
higher when using NRT than when they reported smoking. These women were given lower
doses of NRT to reduce their nicotine exposure. Thus, there did not seem to be much
indication that the women were concomitantly smoking and using NRT.
Dose of counseling intervention—A greater proportion of the women in the CBT
+NRT arm completed four or more sessions (four was median number of sessions) than did
women in the CBT-only arm (70% vs 53%, p=0.02, RD=0.17, 95% CI=0.10–0.24).
Prevalent and sustained abstinence—In intent-to-treat analyses, there were
significant arm differences in the proportion of the women who reported not smoking any
cigarettes in the prior 7 days at both pregnancy follow-ups. Women in the CBT+NRT arm
were more likely to report being abstinent than the women in the CBT-only arm at 7-weeks
post-randomization (RD=0.19, 95% CI=0.08–0.30, p=0.005) and at 38-weeks gestation
(RD=0.16, 95% CI=0.06–0.26, p=0.008) (Table 2). No substantial change in these RDs were
found after controlling for number of counseling sessions; specifically, at 7-weeks post-
randomization, the adjusted RD was 0.16 (p=0.02) and at 38-weeks gestation the adjusted
RD was 0.13 (p=0.03). The arm differences remained when comparing biochemically
validated smoking status: 7-weeks (24% vs 8%, p=0.02); 38-weeks gestation (18% vs 7%,
p=0.04) (Table 3). The results did not change when those assigned to the CBT+NRT arm
who did not use NRT were removed from the analyses. No statistically significant arm
differences were found for 3-month postpartum and sustained abstinence (reported 7-day
point prevalence abstinence at all three timepoints) (Table 2). No site differences in
abstinence rates were found.
The relationship between length of NRT use and cessation was assessed. Logistic regression
was conducted with counseling dose and length of NRT use regressed on cessation at 7-
weeks post-randomization. Among the 122 women, for every 7 days of NRT use, they were
1.25 times (95% CI=1.08–1.47, p=0.003) more likely to self-report 7-day point prevalent
abstinence. Dose of intervention was no longer predictive of cessation (OR=1.29, 95%
CI=0.44–3.73, p=0.64).
Birth outcomes—There was no difference between the CBT+NRT and CBT-only arms in
mean birthweight: 3061 (±661) vs 3132 (±688), respectively, p=0.51. Likewise there was no
arm difference in mean gestational age: 37.9 (±3.1) vs 38.6 (±2.7), respectively, p=0.14.
Serious adverse events—Ten women had missing birth outcome data. Forty-four of the
171 women with data had at least one serious adverse event. Adverse events were, ordered
from most to least frequent: preterm birth (<37 weeks), Neonatal Intensive Care Unit
(NICU) admissions, small-for-gestational-age, placenta abruption, and fetal demise (Table
4). Serious adverse events occurred in 34 of 113 (30%) women assigned to CBT+NRT
versus 10 of 58 (17%) women assigned to CBT-only (RD=0.13, 95% CI=0.00–0.26,
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p=0.07). After adjusting for prior history of preterm birth, these adverse event rates changed
to 27% versus 18% for the CBT+NRT and CBT-only arms, respectively (RD=0.09, 95%
CI=0.05–0.21, p=0.26). Women with adverse events had a mean cotinine value of 189.3
(SD=223.9) versus those who did not have an adverse event of 140.8 (SD=149.4), p=0.85.
Women who reported smoking had higher cotinine values (M=201.0, SD=158.7) than the
women reporting using NRT (M=94.5, SD=129.0).
DISCUSSION
This is the first large trial to show effectiveness of NRT in helping pregnant women quit
smoking. The findings from this trial differ from another large efficacy trial36; compliance
with NRT in the previous trial was very low, and no differences in cessation rates resulted.
Women in the Baby Steps trial used NRT more than 1 week longer than the women in the
Wisborg trial. Further, length of NRT use was positively related to cessation, indicating that
higher compliance might have contributed to the higher cessation rates. In addition, efficacy
of CBT+NRT was nearly threefold over CBT-only; this effect is greater than what has been
found in the general population.30 These results confirm findings from a small pilot study in
which three of 20 women versus zero of 20 women quit smoking in the NRT patch and
control arms, respectively.38 The results from Baby Steps are encouraging given the dearth
of effective interventions for smoking cessation during pregnancy.
Several factors other than NRT (open-label and increased utilization with different forms)
may have contributed to the observed improved effectiveness of the CBT+NRT. Also,
although the women assigned to the CBT+NRT arm had more total counseling sessions than
the women in the CBT-only arm, adjustment for number of sessions did not substantially
change the increased cessation observed with NRT. Thus, the observed arm effect was not
due to the fact that the arms differed in the mean number of counseling sessions. A
comprehensive examination of the effect of counselor adherence to counseling protocols,
both in terms of content and Motivational Interviewing techniques, will be published in a
forthcoming manuscript.
Cessation effects during pregnancy were not statistically significant at 3-months postpartum.
This was due, in part, to more women in the CBT-only arm quitting smoking postpartum.
Cessation rates in the CBT-only arm went from 10% and 7% during pregnancy to 14% at 3-
months postpartum, a doubling from the late pregnancy assessment. Cessation rates for the
women in the CBT+NRT arm had a more linear pattern with rates at 29%, 23%, and 20%, at
the 7-week, 38-week, and 3-months postpartum assessments, respectively. These results
suggest that use of NRT during pregnancy does not improve the likelihood of permanent
smoking cessation.
The cessation rates during pregnancy found in this trial are clouded by the DSMB
suspension of enrollment. Although this study was not powered to detect differences in
adverse pregnancy outcomes, it is hypothesized that improved smoking cessation might lead
to a detectable improvement in pregnancy outcomes. Thus, a stopping rule was included, in
the event of a twofold excess in adverse events. At an interim analysis, the a priori stopping
rule was met with more adverse events occurring in the women in the CBT+NRT arm.
However, the DSMB reported that adverse events likely were not associated with NRT use.
This is partially confirmed by the lower cotinine values found among the women who
reported using NRT compared to those who reported smoking. The observed arm difference
in the adverse event rate was partially confounded by the fact that a greater proportion of
women in the CBT+NRT arm had a history of preterm birth than women in the CBT-only
arm. In the final analysis, after controlling for this known risk factor for subsequent preterm
birth,45 the adverse event rates of the two arms was not statistically different. Further, many
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of the observed “serious adverse events” were preterm births between 35 and 37 weeks, with
no clinical sequelae to the baby. Physiologic studies of NRT in pregnancy31–33 and
previous clinical trials36–38 have not suggested an adverse effect of NRT itself in
pregnancy. The data from the trial cannot support or negate the previous literature about the
harm of NRT use during pregnancy. Future trials are needed to determine the safety and
benefit of NRT to the fetus.
This study has several limitations. Even at the originally planned sample size, power to
detect differences in specific pregnancy outcomes was lacking. In hindsight, randomization
should have been stratified on history of negative pregnancy outcomes. The fact that the
women lost to follow-up had more previous negative birth outcomes, smoked more, and had
tried to quit during a prior pregnancy may affect generalizability. Generalizability also may
be limited by medically excluding those for whom NRT was not advisable. The open-label
design also may have influenced cessation rates. In addition, the unique family stresses
introduced by the wars in Iraq and Afghanistan, which affected a large proportion of the
participants from the Fayetteville NC clinical site, were unanticipated at the beginning of the
study and may also have affected generalizability. Another potential limitation is that
although not statistically significant, more women in the CBT+NRT arm completed surveys;
in intent-to-treat analyses, this may have inflated the difference between arms. However, the
women in the CBT arm were less engaged than those in the CBT+NRT arm in the study, in
general, as indicated by their lower number of counseling sessions completed. This low
engagement may be a sign of inability to quit smoking but also may be due to their
disappointment in not being offered free NRT. Loss to follow-up was relatively high, but
consistent with other studies of smoking cessation in this population.25
Many women who smoke recognize the risks of continuing to smoke during pregnancy, as
evidenced by relatively high quit rates during the first trimester.46 For those unable to quit
on their own, adding NRT to CBT may improve smoking cessation rates during pregnancy.
These results are promising for future trials; however, more data are needed to determine the
safety and benefit of NRT use during pregnancy.
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Figure 1. Flow of participants through the study
“Active refusal” indicates potential participants who were contacted but declined to
participate. “Passive refusal” indicates potential participants with whom contact was not
possible. Once randomized, self-reported smoking status was assessed by telephone
interview 7 weeks after randomization, at 38-weeks gestational age, and at 3-months
postpartum. At each timepoint, “delivered” indicates participants who delivered prior to the
time of assessment; “unable to contact within window” indicates participants who were not
reachable by phone within the 3-week window allowed for contact; “withdrew” indicates
participants who refused further participation in surveys; “declined survey” indicates
participants who declined to respond to the phone interview at that point in time but
indicated willingness to be contacted in the future; and “withdrew” indicates participants
who both refused to participate and did not wish to be contacted at future timepoints.
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Table 1
Participant characteristics
Characteristics Total (N=181) Mean (±)/% CBT-only (N=59) Mean (±)/% CBT+NRT (N=122) Mean
(±)/%
Demographics    
Age (M, SD) 27 (6) 26 (5) 27 (6)
 N (%) N (%) N (%)
Partnered (%) 67 69 66
Education (%)    
  Less than high school 28 31 27
  High school/ GED 31 33 31
  Vocational school 7 10 6
  Some college 28 17 33
  College graduate or higher 5 9 3
Race (%)    
  White 69 73 67
  Black 24 19 26
  Other 8 8 7
Employment (%)    
  Full-time 30 31 30
  Part-time 17 9 21
  Not employed 53 60 49
Site (%)    
  Durham 41 39 42
  Fayetteville 59 61 58
First pregnancy (%) 16 12 18
Weeks of pregnancy at enrollment (M, SD) 15 (3) 15 (3) 14 (3)
Weeks of pregnancy at randomization (M,
SD)
18 (3) 18 (4) 17 (3)
Smoking history prior to pregnancy    
  Cigs smoked daily 30d before pregnant (M,
SD)
19 (9) 20 (8) 19 (9)
  Ever had 24-hr quit attempt (%) 58 61 57
Among those who made 24 hour quit    
  Times made a 24 hour quit attempt (M, SD) 3 (3) 2 (2) 3 (3)
  Longest quit in days (M, SD) 93 (158) 79 (133) 100 (171)
Smoking history in previous pregnancies    
  Ever had 24-hr quit attempt (%) 54 62 50
  Longest quit in days (M, SD) 87 (105) 63 (90) 102 (111)
Current smoking history    
  Cigarettes smoked daily (M, SD) 11 (5) 12 (5) 11 (5)
  Quit at least 24 hours during this pregnancy
(%)
28 29 28
  Desire to quit (M, SD) 6 (1) 6 (1) 6 (1)
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Characteristics Total (N=181) Mean (±)/% CBT-only (N=59) Mean (±)/% CBT+NRT (N=122) Mean
(±)/%
  Nicotine dependence (M, SD) 3 (1) 3 (1) 3 (1)
  Stage of readiness (%)    
  Precontemplation 1 4 0
  Contemplation 7 10 6
  Preparation 92 86 94
 Total (N=152) Median CBT-only (N=52) Median CBT+NRT (N=100)
 (IQR)/% (IQR)/% Median (IQR)/%
Prior pregnancy history (n=152)    
  Number of prior pregnancies median (IQR) 2 (1,4) 2 (1,3) 2 (1,4)
  Number of live births median (IQR) 1 (1,2) 1 (1,2) 1 (1,2)
  Any preterm births (%) 25 12 32
  Full term low birthweight (LBW) (%) 5 5 5
  Premature rupture of membranes (%) 7 10 5
  High blood pressure (%) 19 21 18
  Prior history of miscarriage, ectopic
pregnancy, or stillbirth (%)
50 40 55
CBT, cognitive-behavioral therapy; NRT, nicotine replacement therapy
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Table 2
Unadjusted and adjusted percentages of women’s self-report of 7-day point prevalent abstinence
 Arm p value
 CBT-only CBT+NRTa Unadj. Adjb
Time-point N=59 N=122   
 Unadj (Adj.) Unadj (Adj.)   
7-weeks post-randomization 10% (10%) 29% (26%) 0.005 0.02
38 weeks of pregnancy 7% (7%) 23% (20%) 0.008 0.03
3-month postpartum 14% (14%) 20% (17%) 0.31 0.55
Sustained abstinence 7% (5%) 5% (5%) 0.70 0.94
aCBT+NRT = Cognitive-Behavioral Therapy + Nicotine Replacement Therapy
bAnalysis controlled for number of completed counseling sessions.
Sustained abstinence was defined as reported 7-day point prevalence abstinence at all three timepoints
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Table 3
Unadjusted and adjusted percentages of biochemically validated women’s 7-day point prevalent abstinence
 Arm p value
 CBT-only CBT+NRTa Unadj. Adjb
Time-point N=59 N=122   
 Unadj (Adj.) Unadj (Adj.)   
7-weeks post-randomization 3% (8%) 18% (24%) 0.006 0.02
38 weeks of pregnancy 2% (7%) 14% (18%) 0.01 0.04
aCBT+NRT = Cognitive-Behavioral Therapy + Nicotine Replacement Therapy
bAnalysis controlled for number of completed counseling sessions
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